Rezolute, Inc. (NASDAQ:RZLT – Get Rating) SVP Brian Kenneth Roberts acquired 21,052 shares of the business’s stock in a transaction dated Wednesday, May 4th. The stock was acquired at an average price of $3.80 per share, for a total transaction of $79,997.60. Following the purchase, the senior vice president now directly owns 21,052 shares of the company’s stock, valued at $79,997.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
RZLT stock opened at $3.85 on Friday. The firm has a market cap of $59.89 million, a PE ratio of -1.31 and a beta of 3.27. The company has a debt-to-equity ratio of 0.23, a quick ratio of 12.12 and a current ratio of 12.12. The firm’s fifty day moving average is $3.35 and its 200 day moving average is $4.40. Rezolute, Inc. has a one year low of $2.26 and a one year high of $17.39.
Rezolute (NASDAQ:RZLT – Get Rating) last released its quarterly earnings results on Wednesday, February 9th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.03). Research analysts predict that Rezolute, Inc. will post -3.53 earnings per share for the current fiscal year.
RZLT has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Rezolute from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Wednesday, April 13th. Roth Capital raised their price target on shares of Rezolute from $23.00 to $25.00 in a research report on Wednesday, March 23rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $18.33.
Institutional investors and hedge funds have recently bought and sold shares of the business. Altium Capital Management LP purchased a new position in Rezolute during the third quarter valued at $1,553,000. Oppenheimer & Co. Inc. purchased a new position in Rezolute during the third quarter valued at $92,000. Citadel Advisors LLC lifted its holdings in Rezolute by 0.6% during the third quarter. Citadel Advisors LLC now owns 309,986 shares of the company’s stock valued at $2,300,000 after purchasing an additional 1,998 shares in the last quarter. Millennium Management LLC purchased a new position in Rezolute during the third quarter valued at $265,000. Finally, Northern Trust Corp lifted its holdings in Rezolute by 45.7% during the fourth quarter. Northern Trust Corp now owns 52,293 shares of the company’s stock valued at $250,000 after purchasing an additional 16,394 shares in the last quarter. 48.42% of the stock is currently owned by institutional investors and hedge funds.
About Rezolute (Get Rating)
Rezolute, Inc, a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Receive News & Ratings for Rezolute Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Rezolute and related companies with MarketBeat.com’s FREE daily email newsletter.